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Abstract
Background: Clinical trials of agents targeting epidermal growth factor receptor (EGFR) in esophageal carcinoma
(EC) have indicated a minority subgroup responsive to anti-EGFR therapies. Other investigations suggest increases
in EGFR copy number are associated with poor prognosis in EC, but have used a variety of different techniques and
tested numbers remain small. A validated assay for EGFR copy number in EC is needed, to allow investigation of
EGFR copy number gain as a predictive biomarker for the anti-EGFR responsive subgroup of patients. We
developed a scoring system in EC based upon established systems for EGFR fluorescence in-situ hybridisation (FISH)
in lung cancer, and applied this in a series of 160 UK patients with advanced EC.
Results: Dual colour FISH on formalin fixed paraffin embedded (FFPE) biopsies were scored independently by two
operators as: disomy (score = 1), low trisomy (score = 2), high trisomy (score = 3), low polysomy (score = 4), high
polysomy (score = 5) and amplification (score = 6). EGFR FISH positive cases (scores 5 and 6) were found in 32/160
(20 %) tumours, with high polysomy in 22 (13.8 %) and amplification in 10 (6.3 %). Two independent operator scores
for FISH positivity were 100 % concordant. EGFR FISH positive status was not associated with clinic-pathological
features. EGFR amplification was associated with worse survival (HR = 2.64, 95 % CI 1.04 to 6.71, p = 0.03).
Conclusion: Our FISH scoring system for EGFR in advanced EC identifies a significant subgroup (20.0 %) of FISH positive
patients. EGFR amplification, which is found in 6.3 %, is associated with poor survival. It is not known if there is a role for
EGFR targeted treatment in this subgroup of patients, however we are now utilising this EGFR FISH assay and scoring
system in biopsies from clinical trials utilising anti-EGFR targeted therapies.
Keywords: EGFR Copy Number, Esophageal Carcinoma, Esophago-gastric junctional carcinoma
Background
Esophageal carcinoma (EC) is the eighth most common
malignancy worldwide [1]. The incidence of esophageal
adenocarcinoma (EA), has rapidly increased in the USA,
Europe and Australia over the last 30-50 years [2].
Esophageal squamous cell carcinoma (ESCC) remains
common in Western countries and is the most frequent
histological subtype in the developing world, and the
Middle and Far East [1, 3–5]. Despite advances in
imaging modalities, surgical technique, chemotherapy
and radiotherapy, survival remains poor, with USA and
European five year survival rates of 24.5-39.6 % in
patients presenting with localised disease and 9.8-17.5 %
in the overall EC population [6, 7]. Chemotherapy confers
only modest benefit in metastatic disease with median sur-
vival of only 9-11 months [8], and only half of patients will
complete first line treatment due to toxicity or disease
progression, although 40 % of patients may be fit for
second line treatment [9, 10].
There has been a recent paradigm shift in the treatment
of esophagogastric cancer. In the TOGA study, Bang and
colleagues demonstrated survival benefit using the HER-2
monoclonal antibody trastuzumab over placebo with
capecitabine/5-FU and cisplatin chemotherapy in patients
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with advanced gastro-esophageal junction or gastric
adenocarcinomas overexpressing HER-2 by immunohisto-
chemistry or HER-2 gene amplification by FISH [11].
The primary end point of overall survival was met with
median OS of 13.8 months in the trastuzumab arm
compared to 11.1 months in the chemotherapy alone arm,
p = 0.046. Patients whose tumours had either very high
HER-2 over expression (IHC3+) or HER-2 amplification
confirmed by FISH, achieved a median survival of
17.9 months when treated with trastuzumab plus chemo-
therapy, compared to median survival of 12.3 months
when treated with chemotherapy alone, HR 0.57 (95 % CI
0.41-0.81) [11].
Following this proof of concept of a role for targeted
therapies in esophagogastric cancer, the clinical utility of
novel agents targeting other growth factors have been
investigated in EC.
There are two main classes of targeted therapy; small
molecule tyrosine kinase inhibitors which act intra-
cellularly on tyrosine kinases to prevent induction of
downstream signalling pathways; and monoclonal anti-
bodies which either compete with extracellular ligands
to bind onto growth factor receptors or act directly on
ligands to prevent ligand binding.
Targeted therapies against the Epidermal Growth Factor
Receptor (EGFR) are in routine clinical use. Activation of
the EGFR pathway stimulates intracellular signalling
cascades including the RAF-MEK-ERK pathway which is
involved in regulation of cell cycle progression, cell differ-
entiation, proliferation and apoptosis, the subject of
detailed reviews by Neuzillet et al. and McCrubrey et al.
[12,13]. Activation of the EGFR pathway also initiates the
PI3K-PTEN-Akt pathway, which has key roles in regula-
tion of apoptosis and protein synthesis [14,15]. The EGFR
and its ligands represent ‘druggable’ targets which when
inhibited result in downregulation of growth factor path-
ways and thus anti-cancer effect. The tyrosine kinase
inhibitor gefitinib has demonstrated survival benefit in
EGFR mutated non-small cell lung cancer [16] and cetuxi-
mab, an anti-EGFR monoclonal antibody, improves
survival in KRAS wild type colorectal cancer [17].
Recent trials of the anti-EGFR monoclonal antibodies
cetuximab and panitumumab in combination with
chemotherapy have not shown any overall survival benefit
in EC [18,19]. The COG study, a phase III, randomised,
double blinded trial of gefitinib, a tyrosine kinase inhibitor
targeting EGFR, versus placebo in the second line setting
of esophageal cancer patients did not demonstrate
improvement in overall survival. However, median pro-
gression free survival with gefitinib was significantly
improved from 1.1 to 1.57 months (HR 0.8, 95 % CI 0.66
to 0.96, p = 0.02) as was disease control rate, 24.1 % com-
pared to 15.6 % at eight weeks (p = 0.016) [20]. Patient
reported outcomes were also significantly improved. This
suggests an anti-EGFR therapy responsive subgroup and
highlights the importance of developing a predictive
biomarker for anti-EGFR treatment benefit [20].
Gene copy number changes are frequent in EC in
comparison to other tumour types including tumours in
the gastrointestinal tract, even in the stomach [21].
Previous studies of EGFR gene copy number changes
have suggested an association with poor prognosis in EC
[21]. We thus propose that EGFR gene copy number
changes might prove useful as predictive biomarkers for
targeted therapies against EGFR [22].
EGFR copy number gain, including amplification, in
esophageal and gastric cancers has been identified using
several different methods, which used differing levels of
gain for reporting EGFR amplification and inconsistent
results regarding whether this confers a poor prognosis
(Table 1) [23–32]. Differing classification systems for
significant copy number gain or amplification, distinct
biological differences between gastric cancer and EC,
and some studies not assessing correlation between
EGFR copy number and survival may account for re-
ported disparities. In addition, the majority of previous
studies have been small and undertaken in patients of
differing ethnicities, and several studies were performed
with technology that is no longer in widespread clinical
use (Table 1) [23–32]. No previous study has provided a
classification for EGFR copy number in EC to the degree
that has become routine practice in other tumour types.
FISH is widely recognised as the “gold standard”
diagnostic method for assessing gene copy number gain
in human cancers. FISH for EGFR copy number alter-
ations has been most extensively studied in formalin
fixed paraffin embedded (FFPE) non-small cell lung can-
cer samples. Hirsch and colleagues [33] described four
distinct categories in an analysis of 183 cases: disomy,
trisomy, polysomy and amplification. Amplification was
further classified as low (EGFR/ CEP7 ratio 2.1-3.0) or
high (ratio >3.0). Significant correlation between EGFR
gene copy number by FISH and EGFR protein expres-
sion by immunohistochemistry was identified (p < 0.001);
high gene copy number also showed a trend towards
poorer prognosis.
This principle of gene copy number classification in
lung cancer was developed further by Cappuzzo et al,
categorising EGFR FISH status into six categories with
precise inclusion criteria of FISH positive cases compris-
ing either high polysomy (≥40 % of cells with ≥ 4 copies of
the EGFR gene) or amplification [34]. The concept of
intratumoural heterogeneous amplification was also
introduced, with the amplification criteria expanded
from having an overall ratio of >2.0 to include either
clustered EGFR signal with ratio of ≥2.0 or ≥15 EGFR
copies in ≥10 % cells analysed. In a multivariate ana-
lysis using this criteria, EGFR FISH positive tumour
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status demonstrated significantly improved response
rates (36 % in EGFR FISH positive versus 3 % in
EGFR FISH negative patients; p < 0.001) and overall
survival (median overall survival 18.7 months in
EGFR FISH positive versus 7.0 months in EGFR FISH
negative patients; p = 0.003) in 103 patients with non-
small cell lung cancer being treated with the EGFR
tyrosine kinase inhibitor gefitinib.
Varella-Garcia extended the EGFR FISH positive criteria
to include larger and brighter EGFR signals compared to
CEP7 signal in >10 % of tumour tissue with normal size
EGFR signal in adjacent non- malignant cells, and recom-
mended that fifty cells should be analysed in four distinct
tumour areas [35]. An update providing guidance regarding
sample storage and preparation was issued in 2009 [36].
In light of the potential importance of EGFR as a
target in EC and EGFR copy number as a predictive
biomarker, we adapted the consensus EGFR copy num-
ber analysis FISH assay used in non-small cell lung
cancer as an assay for use in clinical trials and diagnos-
tics in EC. Here we present the findings from applying
this assay to FFPE tissue from 160 patients with
advanced EC, approximately half of whom received
second line treatment.
Results
Patient characteristics
Tumour samples were collected from 160 UK patients
with pre-treated advanced esophageal or type I-II
esophago-gastric junctional tumours. The majority of
samples were diagnostic biopsies from the primary
tumour (88.8 %), with surgical resection specimens
accounting for 10.6 % and one case (0.6 %) was from a
diagnostic liver biopsy. Clinico-pathological features are
summarised in Table 3.
EGFR FISH analysis
All FISH positive cases (EGFR amplified and high
polysomy) scored by two independent observers were
concordant (100 %). Sub-classification of FISH negative
scores was also highly concordant, with a third scorer
needed to agree classification in only 15/160 cases (9.4 %).
Based on the classification criteria described in Table 2,
128/160 (80.0 %) of cases were classified as FISH negative
and 32/160 (20.0 %) were classified FISH positive. In the
EGFR FISH negative group, disomy was present in 45
cases (28.1 %); low trisomy in 47 (29.4 %); high trisomy in
two cases (1.3 %) and low polysomy in 34 cases (21.3 %).
Of the EGFR FISH positive cases, high polysomy was in
Table 1 Frequency of EGFR gene amplification in esophago-gastric cancer
Histology Ethnicity Technique Amplification classification Amplification (%) Amplification impact on prognosis Reference
GC European Southern Blot Not documented 2/30 (6.7 %) Not assessed Lemoine 1991 [23]
GC Chinese FISH ≥ 15 EGFR copies in ≥10 %
tumour cells OR ≥40 % cells with
≥4 EGFR copies OR EGFR/CERP7
ratio ~ 1 but cluster of ≥4EGFR
copies in ≥10 % cells OR EGFR/
CERP7 ratio ≥2 and cluster of
≥4EGFR copies in ≥10 % cells
20/69 (29 %) Not assessed YK 2011 [24]
GC European FISH EGFR/ CEP 7 ratio≥ 2.0 4/82 (4.88 %) Poorer survival of EGFR amplified
cases in multivariate analysis (HR
4.82, 95 % CI 1.32-17.7, p = 0.0176)
Kandel 2014 [25]
ESCC Japanese Southern Blot EGFR/ CEP 7 ratio≥ 2.0 9/42 (21.4 %) Not assessed Itakura 1994 [26]
ESCC Thai FISH Low level: ratio 1.3-2.0,
High level: ratio >2.0
8/15 (49 %) No significant difference in
survival in EGFR amplified cases
Sunpaweravong
2005 [27]
ESCC Japanese FISH/CGH FISH: EGFR/CEP 7 ratio≥ 2.0;
CGH: >4 copies of EGFR gene
16/244 (7 %) No significant difference in
survival in EGFR amplified cases
Kato 2013 [28]
ESCC Japanese FISH Low level: 3-10 EGFR signals/cell;
High level: cluster of EGFR
signals/>10 signals per cell
15/83 (18.1 %) No significant difference in
survival in EGFR amplified cases
Hanawa 2006 [29]
EA and
ESCC
European CISH CISH + ve: >50 % cells with either
tight EGFR clusters or > 4 EGFR
copies per cell
2/16 (12.5 %) Not assessed Janmaat 2006 [30]
EA European FISH Ratio≥ 2.0 or presence of tight
EGFR gene clusters
7/112 (6.25 %) Poorer survival of EGFR amplified
cases in multivariate analysis
(p = 0.0004)
Marx 2010 [31]
EA N. American
NOS
Southern Blot Ratio≥ 2.0 7/87 (8.0 %) Not assessed Miller 2003 [32]
Abbreviations: CGH comparative genomic hybridisation, CISH chromogentic in situ hybridisation, FISH fluorescence in-situ hybridisation, GC gastric cancer,
EA esophageal adenocarcinoma, ESCC esophageal squamous cell carcinoma
Dahle-Smith et al. Molecular Cytogenetics  (2015) 8:78 Page 3 of 9
displayed in 22 (13.8 %) cases and 10 (6.3 %) cases
harboured EGFR amplification (Fig. 1).
Three patterns of amplification were observed, double
minutes, homogenous staining region and heterogeneous
amplification (Fig. 1). Double minutes and homogenous
staining regions in interphase have previously been
described by Martin and colleagues [37]. Most amplified
cases displayed uniform amplification with either a diffuse
specked signal pattern consistent with double minutes or
tightly packed signal clustering representing a homogenous
staining region. A homogenous staining region is caused
by amplicon clustering on a chromosome whereas double
minute amplification is due to multiple copies of
non-centromeric chromosomal fragments containing
EGFR, seen as disseminated signals. Intra-tumoural
heterogeneity for amplification was also observed, and
tumours with ≤50 % of cells exhibiting amplification
were classed as heterogeneous amplification. Of the
ten amplified cases, five were homogenous staining
regions, three cases heterogeneously amplified and
two were double minutes.
Association of EGFR FISH status with clinical and
pathological variables
Using Fisher’s exact test, no association was demonstrated
between EGFR FISH status and gender (p = 0.752), disease
site (p = 0.422), performance status (p = 0.085), body mass
index (p = 0.737), brain metastases (p = 0.361) or number
of prior chemotherapy regimens (p = 0.406) (Table 3). No
association was detected between central review of
histology (one patient with baseline undifferentiated
carcinoma was excluded from analysis) using Pearson X2
test (p = 0.909).
Association between EGFR FISH status and survival
In order to remove the effects of treatment interaction,
the relationship between EGFR gene copy number and
overall survival in the 79 of 160 patients that received
no further treatment was examined. This allowed the
therapy independent prognostic impact of EGFR FISH
status to be examined in the population of advanced
oesophageal cancers that have been, and most likely will
be, evaluated in future clinical trials of anti-EGFR
agents. There was no significant difference in overall
survival in EGFR FISH positive (N = 14) versus negative
(N = 65) patients, (HR 1.55, 95 % CI 0.85 to 2.85, median
overall survival 3.30 v 3.03 months p = 0.15, Fig. 2), but
there is limited power to detect anything except a large
difference due to the small numbers. EGFR amplified
cases (N = 5) had significantly worse overall survival
compared to EGFR non-amplified cases (N = 74), (HR
2.64, 95 % CI 1.04 to 6.71, median overall survival 1.76 v
3.17 months, p = 0.03, Fig. 2).
There was no significant difference in overall survival
between EGFR FISH positive and EGFR FISH negative
cases, or between EGFR amplified and non-amplified
cases in the whole cohort and in patients that received a
variety of further treatments (data not shown).
Discussion
In this study we successfully applied an EGFR FISH clas-
sification previously developed for non-small cell lung
cancer, for use in esophageal cancer and characterised a
series of 160 FFPE samples using dual colour probe
EGFR FISH. Scoring in all FISH positive cases (amplified
and high polysomy; 5 and 6) was concordant between
two independent observers, and very high (90.6 %) for in-
dividual FISH negative categories 1 to 4, with concordance
reached in all cases following third independent scorer
analysis. Survival analysis in patients receiving best sup-
portive care using this classification demonstrated worse
prognosis in FISH amplified cases (p = 0.03).
In our series, 20 % of EC patients were EGFR FISH
positive, representing a significant subgroup of patients
with advanced esophageal cancer with potential up-
regulation of and growth dependency upon the EGFR
pathway. The frequency of EGFR amplification present in
6.3 % (ten cases) is consistent with previous reports (6.25-
49 %) [23–32]. The frequency of FISH amplification is
similar to that seen for the HER-2 receptor [28,38].
Three distinct patterns of amplification were observed,
homogeneous staining regions representing large, bright
Table 2 EGFR FISH classification system adapted from
Varella-Garcia [35]
Tumour classification EGFR status
Disomy: ≤2 copies in ≥90 % cells Negative
Low trisomy: ≤2 copies in ≥40 % cells,
3 copies in 10-40 % cells, : ≤4 copies in <10 % cells
Negative
High trisomy: ≤2 copies in ≥40 % cells,
3 copies in ≥40 % cells, : ≤4 copies in <10 % cells
Negative
Low polysomy: ≥4copies in 10-40 % cells Negative
High polysomy: ≥4copies in ≥40 % cells Positive
Amplification: Any of Positive
-EGFR/CEP7 ratio ≥2
- Small cluster (4-10 copies) or innumerable
tight clusters in >10 % cells
- Larger and brighter EGFR signals v CEP7 signals
in >10 % cells, with EGFR smaller than CEP7 in
adjacent non-tumour cells
- >15 copies of EGFR signal in >10 % tumour cells
INDEPENDANT of EGFR/CEP7 ratio
If amplified, pattern of amplification:
- Homogenous staining region (HSR)
- Double minute (DM)
- Heterogeneous amplification (HA)
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signals caused by amplicon clustering; double minutes
demonstrating fragments of non-centromeric chromo-
some material [37]; and heterogeneous amplification
cases of both double minutes and homogeneous staining
region type. Cases were felt to be heterogeneously ampli-
fied if ≤50 % tumour cells demonstrated amplification.
The issue of intratumoural heterogeneity remains con-
troversial. Different cut-off values of ≤50 % in gastric
and 5-50 % in breast cancers to define heterogeneous
HER-2 amplification [39,40] have been applied and al-
though EGFR copy number heterogeneity has been iden-
tified in non-small cell lung cancer [41] and colorectal
cancer [42] no standardised classification system has
been developed. Cases meeting our EGFR amplification
criteria have significantly worse overall survival com-
pared with non-amplified cases (median overall survival
1.76 v 3.17 months, p = 0.03), in patients not treated
with anti-cancer therapies, confirming EGFR amplifica-
tion as a therapy independent prognostic biomarker in
EC and supporting the use of dual colour EGFR FISH as
a robust method of analysis of EGFR gene copy number.
Further studies are required to determine whether EGFR
amplification in EC is useful as a predictive biomarker to
identify patients suitable for anti-EGFR targeted therapy
and we suggest that the method and scoring system
described here is fit for this purpose.
A lack of standardised biopsies is a limitation of
our study, the majority of tumour samples were from
diagnostic biopsies of the primary tumour (88.8 %),
surgical resection specimens accounted for 10.6 %
and one case (0.6 %) had a diagnostic biopsy from a
metastatic hepatic deposit. Due to the invasive nature
of endoscopy and biopsy, repeat tumour biopsies are
rarely performed in this tumour type outside clinical trials
or when patients are scheduled for surgery. Disease
progression causing dysphagia requiring stent inser-
tion is a potential opportunity for repeat biopsy, to
differentiate, for example, stricture secondary to radi-
ation induced fibrosis from tumour. Repeat endosco-
pies are not without risk and are considered intrusive
for many patients and clinicians, particularly if it will
not alter treatment options.
Fig. 1 EGFR FISH classifications and patterns of EGFR FISH amplification observed. Using dual colour FISH and fluorescent microscopy, EGFR gene
copy number was determined in 160 patients with advanced oesophageal cancer. EGFR FISH negative cases are present in panels a-c, EGFR FISH
positive cases in panels D-F and a heterogeneously amplified case in panel G. The EGFR FISH classification as follows: loss of chromosome
7 (a), disomy (b), trisomy (c), high polysomy (d), amplification (double minute type) (e), amplification (homogenous staining region type)
(f) heterogeneous amplification (g). Blue = DAPI nuclear staining; red signal = EGFR; green signal = chromosome 7 centromere; white arrow = EGFR
amplified cells in a heterogeneous amplified case
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Previous studies of EGFR copy number in EC are
summarised in Table 1. A variety of techniques have
been employed to investigate the frequency of EGFR
copy number gain or amplification in esophago-
gastric cancer, yielding a frequency of 6.25- 49 %
(Table 1) [16–25]. Of the studies using FISH to evalu-
ate EGFR copy number change or amplification, two
were in gastric cancer patients, demonstrating poor
survival in the 4.88 % of European patients with amp-
lification, however survival outcome was not assessed
in 29 % EGFR amplified Chinese gastric cancer pa-
tients [24, 25]. In studies of EC where the prognostic
impact of EGFR amplification by FISH has been
assessed, there are discordant results, perhaps due to
differing scoring criteria and histological tumour sub-
type [27–29, 31].
The distinct biological and molecular features of
gastric cancer and EC, in particular the different fre-
quencies of gene copy number changes, as well as the
lack of a validated classification system for significant
EGFR copy number gain or amplification, may account
for inconsistencies in results. In addition, the majority of
previous studies have been small and undertaken in
patients of differing ethnicities and several studies were
performed with technology that is no longer in widespread
clinical use, making it unclear whether EGFR amplifica-
tion does result in poorer survival.
The frequency of EGFR amplification may be lower in
European and North American populations (6.5 -12.5 %)
when compared to studies in Asian patients (7-49 %),
implying a significant ethnic component to EGFR dys-
regulation in esophago-gastric cancer. Ethnic differences
Table 3 Association of EGFR FISH status with clinicopathological features
All patients (N = 160) EGFR FISH negative (N = 128) EGFR FISH positive (N = 32) P value
Age (mean,SD) 64.02 (9.49) 64.15 (9.64) 63.49 (8.99) 0.725
Gender:
Male 133 (83.1 %) 10.7 (80.5 %) 26 (19.5 %) 0.752
Female 27 (16.9 %) 21 (77.8 %) 6 (22.2 %)
Histology:
Adenocarcinoma 118 (73.8 %) 94 (79.7 %) 24 (20.3 %) 0.909
Squamous cell carcinoma 41 (25.6 %) 33 (80.5 %) 8 (19.5 %)
Undifferentiated carcinoma 1 (0.6 %) 1 (0.6 %) 0 (0.0 %)
Disease site:
Oesophagus 124 (77.5 %) 100 (80.6 %) 24 (19.4 %) 0.422
Type I junctional 16 (10.0 %) 14 (87.5 %) 2 (12.5 %)
Type II junctional 20 (12.5 %) 14 (70.0 %) 6 (30.0 %)
WHO PS:
0 (Asymptomatic) 35 (21.9 %) 32 (91.4 %) 3 (8.6 %) 0.085
1 (Symptomatic but ambulatory) 91 (56.9 %) 72 (79.1 %) 19 (20.9 %)
2 (Symptomatic but resting <50 % of day) 34 (21.3 %) 24 (70.6 %) 10 (29.4 %)
Body Mass Index category:
Underweight 15 (9.4 %) 13 (86.3 %) 2 (13.3 %) 0.737
Normal 83 (51.9 %) 66 (76.5 %) 17 (20.5 %)
Overweight 37 (23.1 %) 28 (75.7 %) 9 (24.3 %)
Obese 17 (10.6 %) 15 (88.2 %) 2 (11.5 %)
Missing data 8 (5.0 %)
Brain metastases
No 158 (98.8 %) 127 (80.4 %) 31 (19.6 %) 0.361
Yes 2 (1.3 %) 1 (50.0 %) 1 (50.0 %)
No. of previous chemotherapies:
1 103 (64.4 %) 83 (80.6 %) 20 (19.4 %) 0.406
2 50 (31.1 %) 38 (76.0 %) 12 (24.0 %)
3 7 (4.4 %) 7 (100.0 %) 0 (0.0 %)
Abbreviations: WHO PS World Health Organisation Performance Status
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in molecular abnormalities have been identified in
NSCLC where patients of Asian origin are more likely
than Caucasians (35 v 11 %) to harbour the EGFR muta-
tions inferring increased benefit from anti-EGFR therapy
[16, 43, 44].
The limited benefit and high toxicity of multi-agent
cytotoxic chemotherapies in esophago-gastric cancer
have prompted investigation of targeted therapies, in-
cluding those targeting EGFR and HER-2. Trastuzumab,
a monoclonal antibody against HER-2, has demonstrated
activity in combination with platinum doublet chemo-
therapy in the 10-15 % patients with gastric cancer and
tumour HER-2 protein overexpression or amplification,
compared to chemotherapy alone [11].
The COG study of gefitinib, versus placebo in the sec-
ond line setting of esophageal cancer patients did not
demonstrate improvement in overall survival in unse-
lected patients. Median progression free survival with gefi-
tinib was significantly improved from 1.1 to 1.57 months
(HR 0.8, 95 % CI 0.66 to 0.96, p = 0.02) as was disease
control rate, 24.1 % compared to 15.6 % at eight
weeks (p = 0.016) [20]. The COG study results suggest
that anti–EGFR tyrosine kinase inhibitor therapies repre-
sent a plausible therapeutic option for a sub-group of
responsive patients. Accordingly, we propose that our
scoring system should be used to explore the value of
EGFR FISH positivity as a predictive biomarker for
response to anti- tyrosine kinase inhibitor therapies, espe-
cially gefitinib [20].
Conclusion
In conclusion, we have shown that EGFR amplification
assessed using our standardised FISH scoring system is a
therapy independent prognostic biomarker of poor out-
come in EC and represents a practical, robust assay useful
for clinical research and clinical practice, particularly for
investigation as a predictive biomarker for anti-EGFR
therapies in clinical trials.
Methods
Patient samples for FISH
Ethical approval was obtained from the North of Scotland
Research Ethics Committee. Esophageal tumour blocks
from 160 patients with advanced EC who had received
prior chemotherapy treatment were analysed (AJCC 7th
Edition, stage IIIB/C or IV), of which 81 went on to re-
ceive further systemic therapy [45]. Survival was measured
in months from day of diagnosis until death. No analysis
of EGFR expression was performed due to insufficient
tumour tissue being available. Karyotype analysis was not
possible as this was a retrospective study using archival
formalin fixed paraffin embedded tissue.
Fluorescence in situ hybridisation (FISH)
Sections of 4 μm thickness cut from FFPE esophageal
tumour blocks were mounted on positively charged
slides and pre-treated according to manufacturer in-
structions (Vysis Paraffin Pre-Treatment Reagent Kit II,
Abbott laboratories, Maidenhead, UK). Briefly, slides
were baked overnight at 50 °C, then deparaffinised in xy-
lene, followed by ethanol rehydration. They were then
washed in Pre-Treatment solution for 10 min and de-
ionised water for three minutes. Following this, slides were
immersed in Protease Buffer II and Protease I solution
(pepsin activity 1:3000-1:3500) for 25 min and after wash-
ing in de-ionised water, were dehydrated in an ethanol
series. Once dry, 10 μl of Vysis EGFR/CEP7 dual colour
probe (Abbott Laboratories) was applied and a coverslip
fixed using rubber cement. The slides were then trans-
ferred to a ThermoBrite StatSpin® (Abbott laboratories)
Fig. 2 Kaplan-Meier survival analysis of patients with advanced oesophageal cancer stratified according to EGFR FISH classification performed in
79 patients with advanced oesophageal cancer who were receiving best supportive care. There was a non-significant trend towards poorer overall
survival (OS) in patients with EGFR copy number gain (≥4 EGFR copies in ≥40 % cells) compared to those with no EGFR copy number gain; HR
1.55, 95 % CI 0.85 to 2.85, median OS 3.30 v 3.03 months p = 0.15. Kaplan-Meier survival analysis in this patient group demonstrated poorer OS in
patients with EGFR amplification compared to EGFR non-amplified cases; HR 2.64, 95 % CI 1.04 to 6.71, median OS 1.76 v 3.17 months, p = 0.03
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programmed to denature at 80 °C for six minutes, followed
by hybridisation at 37 °C for 16 h.
Post- hybridisation, slides were washed in 2XSSC/0.3 %
Igepal (Sigma-Aldrich Company Ltd Dorset, UK) and air
dried in darkness. Once dried, nuclear counter stain con-
taining 4’,6-diamidino-2-phenylindole (DAPI) (Vectashield
mounting medium, Vector Laboratories, Peterborough,
UK) was applied, and a new cover slip was attached. Slides
were stored in darkness at 4 °C.
FISH scoring
Analysis was performed by two independent scorers,
using a fluorescent microscope (AXIO Imager M1, Carl
Zeiss Microscopy, Cambridge, UK) and images recorded
using CytoVision 7.3.1 software (Leica Biosystems,
Newcastle, UK). Three areas of tumour were examined,
with 20 cells counted in each area. EGFR FISH scores
were assigned for FISH negative: disomy (score = 1), low
trisomy (score = 2), high trisomy (score = 3) and low
polysomy (score = 4) and for FISH positive: high polys-
omy (score = 5) and amplification (score =6) (Table 2).
In cases of discordance between the first two scorers,
further analysis was carried out by a third independent
scorer and agreement reached.
Statistical analysis
Relationships between baseline clinico-pathological
features and EGFR mutation status were analysed
using Pearson Chi2 or Fisher’s exact test when cell
counts were ≤5. Hazard ratios with 95 % confidence
intervals, log rank test and Kaplan–Meier curves were
constructed comparing overall survival, defined as time
from diagnosis to death) and progression free survival
(defined as time from diagnosis to progression or death)
in EGFR FISH positive and negative cases, and EGFR
amplified cases versus all other cases in the 79 patients
who did not receive further systemic treatment for their
disease. Statistical analysis was performed using Stata
Version 13.1 (StataCorp LP, Texas, USA).
Abbreviations
EA: Esophageal adenocarcinoma; EC: Esophageal cancer; EGFR: Epidermal
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